Evaluating a new gel treatment for diabetic foot ulcers
Official title: A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers
Run by Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd. · NCT06852976 · Data updated 2026-11-12
This study is testing a new gel treatment for diabetic foot ulcers to see if it helps heal the wounds better than the usual care.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd. Industry-sponsored |
| Drugs / interventions | baricitinib, ruxolitinib |
| Locations | 1 site (Durham, North Carolina) |
| Status | Recruiting |
| Started | March 12, 2025 |
| Main results expected | December 2025 |
| Study ends | December 2025 |
| Registry record updated | March 7, 2025 |
| Trial ID | NCT06852976 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-75 with diabetic foot ulcers that have persisted for at least 12 weeks.
✕Probably not a fit
Patients with systemic infections or those with ulcers larger than 25cm2 will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the safety and efficacy of MDI-1228-mesylate Gel in comparison to standard care for patients with diabetic foot ulcers. Approximately sixty participants will be enrolled and randomized to receive either the gel plus standard care or standard care alone. The primary outcome will be the complete healing rate of the target ulcer after 12 weeks, along with the reduction in ulcer area. The study will include a screening period, treatment phase, and follow-up to monitor outcomes.
Why it matters
Potential benefit: If successful, this treatment could significantly improve healing rates for patients with diabetic foot ulcers.
How similar studies have gone: Other studies have shown promise in treating diabetic foot ulcers with novel topical agents, suggesting potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Willing and able to participate and comply with all trial requirements and able to provide signed and dated informed consent prior to initiation of any trial procedures; 2. Male or female 18-75 years; 3. Meet diagnostic criteria for a diabetic ulcer with the presence of at least one target ulcer that meets the characteristics: * Located on dorsal or plantar surface of foot or below the knee. * Wagner grade 2, ulcerated lesion at or below the knee, without systemic infection. * The target ulcer should be the largest, and all each individual ulcers size should be less than 25cm2. All ulcers will be treated the same as the target ulcer. * Target ulcers persisted for at least 12 weeks prior to enrollment and have been on standard of care for at least 4 weeks prior to enrollment. * There is a minimum 3cm margin between the qualifying Target Ulcer and any other ulcers on the specified foot (post-debridement). Exclusion Criteria: 1. Allergy to the main components or excipients of MDI-1228\_mesylate gel, allergy to JAK inhibitors (tofacitib, baricitinib, ruxolitinib), or individuals with allergic constitution. 2. Skin ulcers or chronic wounds caused by electroshock, chemicals, radioactive material etc. 3. The target ulcer has reduced in size by ≥30% in the last 4 weeks under standard treatment. 4. Those with cancerous ulcers or connective tissue diseases including lupus erythematosus, rheumatoid arthritis, scleroderma, etc.
Where it's running
-
Site 001
Durham, North Carolina, United States Recruiting
Study contacts
- Study coordinator: Amanda Fu, M.D.,MBA
- Email: amanda.fu@d2vclinical.com
- Phone: 3910204908
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BIOxHEAL plus standard care for nonhealing diabetic foot ulcers
A multicenter study tests whether applying BIOxHEAL, a placental-derived biologic, to stubborn diabetic foot ulcers helps more people heal when added to standard wound care.
-
Calcaneal Bone Marrow Cells in Foot/Ankle Surgery Patients
This observational study tests whether routine preoperative blood tests relate to the quality and behavior of mesenchymal stem cells from calcaneal bone marrow in adults undergoing foot or ankle surgery.
-
L-Carnitine as an add-on for healing diabetic foot ulcers
This study tests whether taking L-Carnitine helps wound healing in adults with diabetic foot ulcers, alongside standard diabetes and wound care.
-
THERAVEX Tissue Care Spray Plus for Healing of Skin Wounds and Ulcers
This observational review tests whether THERAVEX Tissue Care Spray Plus, used with standard wound care, helps heal various skin wounds and chronic ulcers in adults.
-
Pulsating electromagnetic field therapy for diabetic foot ulcers
This trial tests whether a PEMF device called CRAD ULCER X-01 helps heal chronic diabetic foot ulcers when added to standard wound care.
-
Transverse tibial bone transport to help heal chronic diabetic foot ulcers
This study tests a surgical approach called transverse tibial bone transport to see if it can help heal long‑lasting diabetic foot ulcers and prevent limb loss in adults with limited treatment options.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.